Industry Experts in
Health Economics

Our People. Your Success.

BresMed was established in 2006, and we now have more than 140 staff based in the UK, India, Ireland, the Netherlands and the USA. We are an independent health economic and outcomes research consultancy.

“BresMed is a great consultancy to work with – they deliver very tailored-solutions to your needs and importantly demonstrate flexibility in terms of accommodating changing timelines as is the case when it comes to HTAs.”

Health Economics Senior Manager, Amgen (2013)

“When working on a series of complex and fast approaching HTA submissions, you could not wish for a better team to work with than BresMed. Their level of expertise forces you to consider all options and no stone will be left unturned. Their very effective project management coupled with their ability to deliver on schedule means that your submissions will go in with the highest chance of success.”

Senior Market Access Manager Oncology, Gilead (2014)

“My experience has been very positive through all projects we have done together with the BresMed team. You are all very knowledgeable and flexible, and always giving good advice on the best approach to take. BresMed has always delivered on time with a high quality. In the current project with the literature review I must say you and your team have been extremely patient and flexible, much more than you can ever expect from a vendor."

Global Head Market Access, Sirtex (2015)

"BresMed embraced our challenging scope and timelines and we are really pleased with the high quality deliverables which provided great insights to aid our internal decision making.”

Director, Market Access, GE Healthcare (2016)

“BresMed delivered outstanding work. Their resilience and excellent team working with the Amgen HTA team contributed significantly to the positive outcome we achieved.”

Head of Health Economics, Amgen UK & Ireland (2017)

“BresMed provided powerful strategic insight to help inform our early asset development. They offered a balanced view of risks and opportunities whilst consistently delivering exceptional quality work which I am confident can withstand scrutiny from the UK HTA bodies.”